The Secrets of a Serial Entrepreneur: Featuring Jay Shepard

Program Overview

What does it take to be a CEO? Have a problem you're itching to get feedback on? Want to find out how another CEO has launched not one, but several successful life sciences companies? Join us on May 27th to pick the brain of one of the most successful biotech serial entrepreneurs in the business.

Jay Shepard has been in the healthcare game for 32 years and you name it, he has seen it. He's been involved in or led the launch of 18 products, approval of 10 products and sale of 4 pharmaceutical businesses. Now an Executive Partner with Sofinova, Jay can share his expertise from both a CEO and investor perspective. Don't reinvent the wheel, when all it needs is fixing. Swing by JLabs to hear Jay recount his career successes and challenges; the good, the bad and the ugly; and the ones he wish he could have back.

The Executive Speaker Series provides an intimate forum for biotech veterans and experts to share their career successes and challenges. The accomplished speakers share their lessons learned throughout their professional adventure to an audience of entrepreneurs getting ready to embark on a similar path. The series is an interactive and inspiring experience.

About Jay Shepard | Executive Partner, Sofinnova

Jay joined Sofinnova in 2008, and SVP VIII is his second Sofinnova fund. He has over 32 years of experience in the pharmaceutical, biotechnology and drug delivery arenas. Prior to re-joining Sofinnova, Jay was President & CEO of NextWave Pharmaceuticals, a pediatric focused therapeutics company acquired by Pfizer in a deal valued up to $700M. From 2008-2010, Jay was an Executive in Residence at Sofinnova Ventures. Prior to this, Jay was President & CEO of Ilypsa, a nephrology therapeutics company acquired by Amgen for $420M. After the Ilypsa acquisition, Jay helped with Ilypsa's spin-out company, Relypsa, serving as interim President & CEO. Before Ilypsa, Jay served as VP, Commercial Operations at Telik. He was also VP in the Commercial Operations group at Alza Pharmaceuticals, acquired by Johnson & Johnson in late 2001 for $12B. Jay currently serves on the board of directors at Versartis, as the executive chairman. He is a board member of Bullet Biotechnologies, Marinus Pharmaceuticals, Durect Corporation and the Santa Clara University Entrepreneurial School. Read More»

Agenda

11:30 AM | Registration, Lunch, and Networking
12:00 PM | Presentation, Interview and Q&A
01:00 PM | Program Close

Who Should Attend

Life science and biotech entrepreneurs, industry executives, founders and CEOs of start-ups

Fees

Academic/Student Rate | $20
General Public | $35
On-site | $45

Location

Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121

Janssen Labs is part of Johnson & Johnson’s external R&D engine and provides a capital-efficient, resource-rich environment where emerging companies can transform the scientific discoveries of today into the breakthrough healthcare products of tomorrow. The 40,000 square foot flagship facility in San Diego at Janssen’s West Coast Research Center features core research labs hosting specialized capital equipment, shared administrative areas and individual bench, wet lab and office modules on a short term basis. Companies pay only for the space they need, with an option to quickly expand when they have the resources to do so. An operations team allows our companies to focus on the science and our business team provides access to education, experts and funding partners. Janssen Labs is a no strings attached, open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen. For more information, visit www.janssenlabs.com.

Johnson & Johnson Innovation, LLC focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit: www.jnjinnovation.com.